Skip to main content
SpringerLink
Log in

Hypertension

Endothelin-receptor antagonists for treating hypertension

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some uncertainty.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423–1431 (2009).

    Article  CAS  Google Scholar 

  2. Saito, Y., Nakao, K., Mukoyama, M. & Imura, H. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 322, 205 (1990).

    CAS  PubMed  Google Scholar 

  3. Smolander, J. et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin. Pharmacol. Ther. 85, 628–634 (2009).

    Article  CAS  Google Scholar 

  4. Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403–1419 (2008).

    Article  CAS  Google Scholar 

  5. Gaddam, K. K. et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch. Intern. Med. 168, 1159–1164 (2008).

    Article  CAS  Google Scholar 

  6. Gonzaga, C. C. & Calhoun, D. A. Resistant hypertension and hyperaldosteronism. Curr. Hypertens. Rep. 10, 496–503 (2008).

    Article  CAS  Google Scholar 

  7. Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655–664 (2009).

    Article  Google Scholar 

  8. Weir, M. R. & Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol. (in press).

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, 21201, MD, USA

    Matthew R. Weir

Authors
  1. Matthew R. Weir
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weir, M. Endothelin-receptor antagonists for treating hypertension. Nat Rev Nephrol 6, 192–194 (2010). https://doi.org/10.1038/nrneph.2010.14

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.14

  • Springer Nature Limited

Search

Navigation